FDA Approves Exelixis’ Lead Therapy for Previously Treated Liver Cancer Patients

“This new indication is an important treatment advance for patients with this aggressive form of liver cancer, a community in need of new therapeutic options.”

– Michael M. Morrissey, Ph.D.,
President and Chief Executive Officer

Exelixis Clinical Development Program

Explore our diverse pipeline
through a new interactive chart.

Helping Patients Recover Stronger and Live Longer

We drive to deliver results and new
medicines to treat and defeat cancer,
giving patients hope for the future.

Advancing Science for Medicines that Matter

Best-in-class medicines begin
with smart drug design to target
multiple pathways and work in
combination regimens.

Accelerating Innovation Through High-Impact Relationships

We maximize results and expand
possibilities for patients through
partnerships and collaborative trials.

Cancer is our Cause

We strive to develop effective, tolerable and durable
treatments so patients with cancer can thrive

Breakthroughs come from collective experience, and ours is in the field of oncology. To date, three medicines discovered by Exelixis researchers are available to treat patients living with certain types of kidney cancer, thyroid cancer and advanced melanoma.

Join Us

At Exelixis, everyone leads in our collective quest to drive for results so patients can have hope for remission.